Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates

Medical Mycology

Volumn 52, Issue 2, 2014, Pages 131-139

  Walraven, Carla J ^a,b   Bernardo, Stella M ^a,b   Wiederhold, Nathan P ^c,d   Lee, Samuel A ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

antifungal therapy; biofilms; Candida albicans

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; CRYSTAL VIOLET; ECHINOCANDIN; MICAFUNGIN; ANTIFUNGAL AGENT; GLUCOSYLTRANSFERASE; LIPOPEPTIDE; MEMBRANE PROTEIN; MUTANT PROTEIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCANNING ELECTRON MICROSCOPY; CANDIDIASIS; DRUG EFFECTS; ELECTRON MICROSCOPY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; STAINING; ULTRASTRUCTURE;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; ECHINOCANDINS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPEPTIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON; MUTANT PROTEINS; STAINING AND LABELING;

EID: 84942117934     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myt007     Document Type: Article

References (40)

1. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029
2. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893
3. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482
4. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299
5. Arendrup MC, Perlin DS, Jensen RH, et al. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother 2012; 56: 2435-2442
6. WiederholdNP. Attenuation of echinocandin activity at elevated concentrations: A review of the paradoxical effect. Curr Opin Infect Dis 2007; 20: 574-578
7. Zaas AK. Echinocandins: A wealth of choice-how clinically different are they? Curr Opin Infect Dis 2008; 21: 426-432
8. Spreghini E, Orlando F, Tavanti A, et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 2012; 67: 2195-2202
9. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008; 62: 153-155
10. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: Evidence for echinocandin- specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-2259
11. Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin andmicafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008; 27: 127-131
12. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother 2008; 61: 1140-1144
13. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-3088
14. Miceli MH, Bernardo SM, Lee SA. In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms. Int J Antimicrob Agents 2009; 34: 500-502
15. Hernandez S, Lopez-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-1383
16. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 2006; 50: 2892-2894
17. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26: 877-880
18. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-769
19. Pfaller MA, Boyken L, Hollis RJ, et al. Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006; 44: 3533-3538
20. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the sentry antimicrobial surveillance program (2008-2009). Int J Antimicrob Agents 2011; 38: 65-69
21. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 2058-2063
22. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273
23. Wiederhold NP, Grabinski JL, Garcia-Effron G, Perlin DS, Lee SA. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother 2008; 52: 4145-4148
24. Gillum AM, Tsay EY, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198: 179-182
25. . ReferenceMethods for Broth Dilution Antifungal Susceptibility Testing of Yeasts; approved standard, third edition. CLSI document M27-A3. Wayne, PAClinical and Laboratory Standards Institute; 2008
26. Ramage G, Lopez-Ribot JL. Techniques for antifungal susceptibility testing of Candida albicans biofilms. Methods Mol Med 2005; 118: 71-79
27. Bernardo SM, Lee SA. Candida albicans SUR7 contributes to secretion, biofilm formation, and macrophage killing. BMC Microbiol 2010; 10: 133
28. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorumsensing molecule. Appl Environ Microbiol 2002; 68: 5459-5463
29. Bizerra FC, Melo AS, Katchburian E, et al. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 2011; 55: 302-310
30. Kojic EM,Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-267
31. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-1780
32. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: An update. Eukaryot Cell 2005; 4: 633-638
33. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293-1297
34. Shields RK, Nguyen MH, Du C, et al. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob Agents Chemother 2011; 55: 2641-2647
35. Szilagyi J, Foldi R, Bayegan S, Kardos G, Majoros L. Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemother 2012; 24: 18-25
36. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160-3161
37. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: Possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146-5148
38. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005; 51: 173-178
39. Bachmann SP, VandeWalle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002; 46: 3591-3596
40. Ferreira JA, Carr JH, Starling CE, de Resende MA, Donlan RM. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob Agents Chemother 2009; 53: 4377-4384.